表紙
市場調査レポート

抗血栓剤:世界の産業と市場の展望

Antithrombotic Drugs: World Industry and Market Prospects 2015-2025

発行 Visiongain Ltd 商品コード 262260
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=133.97円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
抗血栓剤:世界の産業と市場の展望 Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
出版日: 2015年03月19日 ページ情報: 英文 188 Pages
概要

抗血栓剤には、主に抗血小板薬、抗凝固薬および線維素溶解薬などがあり、2012年における主導的な治療分野は抗血小板薬によるものでした。今後、患者人口の増加により抗血栓剤市場の成長が促進される一方で、ジェネリック製品との激しい競争が市場の成長を阻害する脅威となります。2014年以降は、抗凝固薬が同市場を主導することが予見されています。

当レポートでは、世界の抗血栓剤市場を取り上げ、血液凝固のメカニズムおよび疾患の概要をまとめ、抗血小板薬や抗凝固薬などの市場も含めた市場動向、市場発展促進・阻害要因を調査分析し、市場における主要製品および研究開発パイプラインにおける製品をまとめ、2015年から2025年までの市場予測および主要国市場の予測を提示するとともに、主要企業のプロファイルをまとめるなど、概略下記の構成でお届けいたします。

第1章 レポート概要

第2章 血液凝固:メカニズム、疾患および現在の治療法

  • 鬱血と凝固の理解
  • 血栓症とは
  • 血栓症の合併症
  • 抗血栓剤による治療

第3章 抗血栓剤:世界市場

  • 世界の抗血栓剤市場、2013年・2014年
  • 包括的な売上予測、2015-2025年
  • 抗血栓剤市場に影響を及ぼす発展促進・阻害要因
    • 患者人口の増加が市場の成長を促進
    • ジェネリック製品との激しい競争が市場の成長を阻害する脅威に
  • 治療分野別抗血栓剤市場:売上・市場シェア予測
  • 治療分野別抗血栓剤世界市場の将来:グループ化された売上予測
  • 抗凝固薬:2014年以降市場を主導
  • 抗凝固薬:2014年は第2の薬効分類
  • 今後も線維素溶解薬が抗血栓剤市場に不可欠なものとして存続

第4章 市場における主要製品

  • PlavixとLovenoxが、ジェネリック製品との競争が存在する中、依然として2012年および2013年の市場リーダー
  • 主導的な抗血栓剤:売上・市場シェアの比較
  • 2025年に向け、最も高い成長率を達成する薬品は?
  • Plavixは14のジェネリック製品との競争に直面、将来の展望は?
  • Lovenox:EUにおいてバイオ後続品との競争が見込まれる
  • Xareltoが2014年の主導的な抗凝固薬
  • Xa因子直接阻害剤市場を主導
  • 2014年も成長し続けたPradaxa
  • Activaseが競争の少ない線維素溶解薬市場を主導
  • EffientがBrilintaと競合し、Plavixがジェネリック製品と競合
  • Aspirin Cardio:最も収益性の高いアセチルサリチル酸
  • AngiomaxはPradaxaに直接トロンビン阻害薬市場のシェアを取られている
  • Pletalはジェネリック製品との競争および欧州における使用規制に直面
  • Aggrenoxは米国で予想以上に早い段階でジェネリック製品との競争に直面する見込み
  • SandozのEnoxaparin Sodium:売上予測
  • Fragminがジェネリック製品との競争からLovenoxとの戦いに直面
  • Brilinta:調査に直面
  • Eliquis:市場への参入の遅れは取り込みに影響するか
  • Arixtra:AspenはGSKから国際的な権利を取得
  • 新規承認薬
    • Zontivity:最新承認薬
    • Lixiana/Savaysa:他の地域市場へ拡大

第5章 主要国市場

  • 2013年、2014年における抗血栓剤売上の上位国
  • 抗血栓剤の主要国:売上と市場シェアの比較
  • 2025年までに最も急成長する国
  • 米国:2014-2025年に抗血栓剤市場を主導
  • EU5カ国:バイオ後続品の認可ガイドラインは変更されるのか
  • 日本:人口の高齢化が2015-2025年において抗血栓剤の需要を刺激
  • 中国抗血栓剤市場が市場シェアを獲得
  • ブラジル抗血栓剤市場:ユニバーサルヘルスケアの拡大に伴い堅調な成長
  • インド抗血栓剤市場は政府医療支出の制約に妨げられる
  • ロシア抗血栓剤市場:医療関連資金の不足が拡大的成長を妨げる

第6章 抗血栓剤開発パイプライン

  • 抗血栓剤の研究開発パイプライン:概要
  • 抗血小板薬研究開発パイプライン
  • 抗凝固薬の研究開発パイプライン
  • 線維素溶解薬の研究開発パイプライン
  • その他の抗血栓剤の研究開発パイプライン

第7章 抗血栓剤市場における主要企業

  • 2014年における主要な抗血栓剤メーカー
  • Sanofiが市場をリードするが、その地位は脅威に晒されているのか
  • Boehringer Ingelheimが市場シェアを獲得
  • Bayerが2種類の抗血栓剤を販売
  • Johnson & Johnsonは制約された製品ポートフォリオで成功を収めることが可能
  • Genentechは市場シェアを保持する
  • Medicines Companyの位置づけは新薬の発表によって強化される
  • Eli Lilly:市場における位置づけはEffientの成否次第
  • 大塚製薬:制約された抗血栓剤ポートフォリオ
  • Pfizer:徐々にシェアを拡大
  • Bristol-Myers Squibbは2013年に大幅に市場シェアを失った

第8章 抗血栓剤市場の定性分析

  • 2015年における抗血栓剤市場の強みと弱み
  • 市場が直面する機会と脅威
  • 抗血栓剤市場に影響を及ぼす社会的、技術的、経済的、および政治的要因

第9章 調査インタビュー

  • インタビュー:Sanjay Bhanot博士、Clinical Development and Translational Medicine 副所長、Isis Pharmaceuticals, Inc.
  • インタビュー:Marcelo A. Lima博士、サンパウロ連邦大学(ブラジル)生化学学科、研究フェロー・分子生物学教授

第10章 調査から得られた結論

  • 世界の抗血栓剤市場
  • 主要国市場
  • 産業における動向

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0037

Treating thrombosis - new analysis showing trends, R&D and revenue forecasts

See the future of antithrombotic medicines. For those treatments you can now get new sales predictions, also exploring research and development. Discover business potentials. And assess results, trends, technologies, therapies and opportunities.

Visiongain's updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your research, analyses and influence.

Please read on to explore those drug sales and find what that industry could earn in future. Forecasts to 2025 and other analyses explain and predict the antithrombotics market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

That study also shows 84 tables, 69 charts and two interviews with authorities in that field.

There you assess the future of treatments to prevent blood clotting and dissolve blood clots. And the following sections explain what our new investigation gives.

Forecasting of that world market and its segments - what does the future hold?

What're the secrets of that industry's progress? Discover in our report overall world revenue prediction to 2025 for antithrombotic medicines, with discussions.

Also find individual revenue forecasts to 2025 for eight therapeutic submarkets at world level:

  • Anticoagulants
  • Antiplatelet agents
  • Fibrinolytic treatments.

And you get forecasts for these anticoagulant drug classes:

  • Direct factor Xa inhibitors
  • Heparins
  • Direct thrombin inhibitors
  • Vitamin K antagonists
  • Other therapeutics (grouped forecast).

There assess outlooks for sales expansion, hearing where you could profit. You investigate competition and rising sales. And you examine the clinical and commercial possibilities.

And also find top medicines' potentials.

Predictions of leading products' sales

How will individual drugs perform to 2025 at world level? Our study forecasts revenues of 14 brands. Assess products, including these:

  • Plavix
  • Lovenox
  • Xarelto
  • Pradaxa
  • Activase
  • Effient
  • Aspirin Cardio
  • Pletal.

2

There you find drugs and years with highest predicted sales. You also examine competitors. So discover what's happening, understanding challenges, trends, competition and opportunities.

That work also shows geographical revenue predictions.

National markets - what outlooks for revenues?

In developed and developing countries, many opportunities for producers and sellers of antithrombotic medicines will occur from 2015 to 2025. See where, how and what's possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy and Spain (EU5)
  • BRIC nations - Brazil, Russia, India and China.

There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and demands.

3

Events affecting developers, producers and sellers of those cardiovascular medicines

That report also explains issues, forces and events affecting the antithrombotics industry and market from 2015, including these:

  • Progress and outlooks for preventing and treating thrombosis, pulmonary embolism, stroke, acute coronary syndrome (ACS) and related cardiovascular disorders
  • Expanding patient populations stimulating demand for those blood regulating medicines
  • Competition from generics and biosimilars, including discussion of regulatory guidelines for biosimilar low-molecular-weight heparin (LMWH).

And these issues, among others:

  • Governmental healthcare spending and effects on that market's performance
  • R&D in antiplatelet agents, anticoagulants, heparins, vitamin K antagonists, direct thrombin inhibitors, direct factor Xa agents, fibrinolytics and other antithrombotics
  • Development of antidotes for anticoagulation drugs, and the commercial effects.

There you investigate what stimulates and restrains that industry and affects its results.

Analysis of companies and potential for rising sales - what revenues possible?

What happens next? Our study predicts that world market will rise to $22.4bn in 2019, with high revenues from 2015 to 2025.

You also see what organisations hold most potential:

  • Sanofi
  • Boehringer Ingelheim
  • Bayer
  • Johnson & Johnson
  • Genentech.

And also these firms, among others:

  • The Medicines Company
  • Eli Lilly
  • Otsuka
  • Pfizer
  • Bristol-Myers Squibb.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from that applied haematology.

4

Ways Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 helps

In particular, our new investigation gives you this knowledge:

  • Antithrombotic revenues to 2025 at overall world level, and also for 8 submarkets and 14 products - assess outlooks for production, marketing and sales
  • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors, rising companies and new entrants - explore portfolios, results, strategies, R&D and outlooks for success
  • Review of R&D by therapy group - investigate progress in research and development, finding technological and medical potentials
  • Interviews with other authorities - discover what experts in that field think, say and do, helping you stay ahead
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.

Information found nowhere else, helping your searches, analyses and plans

Our study gives independent analysis. There you get competitive intelligence found only in our work, finding where progress and money lie. You see what's possible from 2015.

With that data you're less likely to fall behind in knowledge or miss opportunity. And find in our report how you could save time and effort, also helping your planning, decisions, authority and competing.

5

Our new investigation is for everyone analysing medications for thrombosis treatment and prevention. There you discover trends, discussions and sales predictions. Avoid missing out in commercial knowledge.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Antithrombotic Drugs
  • 1.2 Why Should You Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain
  • 1.10 Glossary of Abbreviations

2. Blood Clotting: Mechanisms, Disorders and Current Treatments

  • 2.1 Understanding Haemostasis and Coagulation
  • 2.2 What is Thrombosis
  • 2.3 Complications of Thrombosis
    • 2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
    • 2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
    • 2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
  • 2.4 Antithrombotic Drug Treatment

3. Antithrombotic Drugs: World Market 2015-2025

  • 3.1 The World Antithrombotic Drug Market in 2013 and 2014
  • 3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2014-2025
  • 3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
    • 3.3.1 An Increasing Patient Population Drives Market Growth
    • 3.3.2 Intense Competition from Generics Threatens to Restrain the Market
  • 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
  • 3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
  • 3.6 Anticoagulant Drugs: Leading the Market from 2014 Onwards
    • 3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
    • 3.6.2 Heparins: Second-Leading Anticoagulant Class in 2013
    • 3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2013 and 2014
    • 3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
  • 3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2014
  • 3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4. Leading Products in the Market: Prospects, 2015-2025

  • 4.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition
  • 4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2019 and 2025
  • 4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2025?
  • 4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
    • 4.4.1 Branded Competition for Plavix?
  • 4.5 Lovenox: Biosimilar Competition in the EU is Expected
  • 4.6 Xarelto: Leading Antithrombotic of 2014
  • 4.7 Pradaxa's Continued Growth in 2014
  • 4.8 Activase Leads the Fibrinolytics Market, With Little Competition
  • 4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
  • 4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
  • 4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
  • 4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
  • 4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
  • 4.14 Sandoz's Enoxaparin Sodium: Revenue Forecast 2014-2025
  • 4.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
  • 4.16 Brilinta/Brilique: Investigation Closed in 2014
  • 4.17 Eliquis: Will Late Entry to the Market Affect Uptake?
  • 4.18 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
  • 4.19 New Approvals in the Antithrombotic Drugs Market, 2014
    • 4.19.1 Zontivity: The Newest Approval in Antithrombotics
    • 4.19.2 Lixiana/Savaysa: Expansion into Other Regional Markets

5. Leading National Markets, 2014-2025

  • 5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2013 and 2014?
  • 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2019 and 2025
  • 5.3 Which National Markets Will Grow Fastest to 2025?
  • 5.4 The US: Dominating the Antithrombotic Drug Market Through 2014-2025
  • 5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
    • 5.5.1 Germany Leads the EU5
    • 5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
    • 5.5.3 UK: Pharmaceutical Price Regulation Scheme
    • 5.5.4 Italy's Healthcare System - Advantages Conducive to Business
    • 5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
  • 5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2015-2025
  • 5.7 Chinese Antithrombotic Drug Market Will Capture Market Share
  • 5.8 Brazilian Antithrombotic Drug Market 2015-2025: Strong Growth as Universal Healthcare Coverage is Expanded
  • 5.9 Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?
  • 5.10 Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth

6. Antithrombotic Drug Development: R&D Pipeline

  • 6.1 The R&D Pipeline for Antithrombotic Drugs: Overview
  • 6.2 The Antiplatelet Drug R&D Pipeline in 2014
    • 6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
    • 6.2.2 The Medicines Company's Kangrexel (Cangrelor) Awaits Approval
  • 6.3 The R&D Pipeline for Anticoagulants, 2014
    • 6.3.1 Heparins: Little R&D Activity in 2014
      • 6.3.1.1 Will Development of Momenta's Adomiparin Continue?
      • 6.3.1.2 The Discontinuation of Semuloparin
    • 6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
    • 6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
    • 6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
    • 6.3.5 Portola Pharmaceuticals' Betrixaban
    • 6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
  • 6.4 The Fibrinolytics R&D Pipeline, 2014
    • 6.4.1 Lundbeck's Desmoteplase: Failed to Meet Primary Endpoint in Phase III
    • 6.4.2 Bharat Biotech and ThromboGenics' THR-100
  • 6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2014
    • 6.5.1 Kyowa Hakko Kirin's KW-3357: Filed in Japan, 2014
    • 6.5.2 Asahi Kasei Pharma America's ART 123
    • 6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
    • 6.5.4 Isis Pharmaceuticals' ISIS-FXI Rx

7. Leading Companies in the Antithrombotic Drug Market

  • 7.1 Leading Antithrombotic Drug Manufacturers in 2014
  • 7.2 Sanofi Leads the Market, but is its Position Under Threat?
  • 7.3 Boehringer Ingelheim Captures Market Share
  • 7.4 Bayer Markets Two Antithrombotic Drugs
  • 7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio
  • 7.6 Genentech Will Retain Market Share
  • 7.7 The Medicines Company's Position Will be Bolstered by the Launch of its New Drug
  • 7.8 Eli Lilly: Market Position is Dependent on Success of Effient
  • 7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
  • 7.10 Pfizer: A Gradually Increasing Share of the Market
  • 7.11 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013

8. Qualitative Analysis of the Antithrombotic Drugs Market, 2015

  • 8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2015
    • 8.1.1 Thrombotic Disease: Management Rather Than Cure
    • 8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
  • 8.2 Opportunities and Threats Facing the Market 2015-2025
    • 8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
    • 8.2.2 Further Development of Existing Drugs
    • 8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
    • 8.2.4 The Threat of Generic Competition
    • 8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
    • 8.2.6 High Risk of Investment in New Drug Development
    • 8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
  • 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2015-2025
    • 8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
    • 8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
    • 8.3.3 Economic Factors
      • 8.3.3.1 Cost Cutting in the EU and the US
      • 8.3.3.2 Free Trade within the EU Presents Challenges
    • 8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?

9. Research Interviews

  • 9.1 Interview with Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc.
    • 9.1.1 Isis Pharmaceuticals Antithrombotic Drugs Pipeline
    • 9.1.2 ISIS-FXIRx Phase II Results
    • 9.1.3 Trends in the Antithrombotic Drug Market, 2015-2025
  • 9.2 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil
    • 9.2.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
    • 9.2.2 Heparin vs. Novel Oral Anticoagulants
    • 9.2.3 Unmet Needs in Brazil and Worldwide
    • 9.2.4 Trends in the Antithrombotic Drug Market

10. Conclusions from Our Study

  • 10.1 The World Market for Antithrombotic Drugs 2015-2025
    • 10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
  • 10.2 The Leading National Markets 2015-2025
  • 10.3 Trends in the Industry
    • 10.3.1 The Market Will Recover From Plavix Decline
    • 10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
    • 10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
    • 10.3.4 High Barriers to Market Entry and a Limited Pipeline - The Implications

List of Tables

  • Table 1.1 Antithrombotic Drugs Market Forecast, 2014-2019
  • Table 1.2 Antithrombotic Drugs Market Forecast, 2019-2025
  • Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
  • Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
  • Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
  • Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.9 The Warfarin Market: Companies and Year of Introduction
  • Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Table 4.4 Plavix: Key Facts, 2014
  • Table 4.5 Selected Generic Competitors Approved by the FDA, 2014
  • Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.7 Lovenox: Key Facts, 2014
  • Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.9 Xarelto: Key Facts, 2014
  • Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.11 Pradaxa: Key Facts, 2014
  • Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.13 Activase: Key Facts, 2014
  • Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.15 Effient: Key Facts, 2014
  • Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.17 Aspirin Cardio: Key Facts, 2014
  • Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.19 Angiomax/Angiox: Key Facts, 2014
  • Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.21 Pletal: Key Facts, 2014
  • Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.23 Aggrenox/Asasantin: Key Facts, 2014
  • Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.25 Sandoz's Enoxaparin Sodium: Key Facts, 2014
  • Table 4.26 Sandoz's Enoxaparin Sodium: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.27 Fragmin: Key Facts, 2014
  • Table 4.28 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.29 Brilinta: Key Facts, 2014
  • Table 4.30 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.31 Eliquis: Key Facts, 2014
  • Table 4.32 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.33 Arixtra: Key Facts, 2014
  • Table 4.34 Zontivity: Key Facts, 2014
  • Table 4.35 Lixiana/Savaysa: Key Facts, 2014
  • Table 5.1 Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 5.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 5.3 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
  • Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2014
  • Table 6.2 Selected Candidates in the Heparins Pipeline, 2014
  • Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014
  • Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2014
  • Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014
  • Table 6.6 The Fibrinolytics R&D Pipeline, 2014
  • Table 6.7 Other Antithrombotic Drugs in Development, 2014
  • Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014
  • Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014
  • Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2014
  • Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014
  • Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2014
  • Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2014
  • Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2014
  • Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014
  • Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2014
  • Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014
  • Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2015
  • Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2015-2025
  • Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2015-2025

List of Figures

  • Figure 2.1 Diagram Depicting the Coagulation Cascade
  • Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013
  • Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Share (%), 2014
  • Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m),
  • 2014-2025
  • Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2019
  • Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2025
  • Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2014-2025
  • Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
  • Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2014-2025
  • Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2015-2025
  • Figure 3.11 Heparins: Revenue Forecast ($m), 2014-2025
  • Figure 3.12 The Heparins Market: Drivers and Restraints, 2015-2025
  • Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2014-2025
  • Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2015-2025
  • Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2014-2025
  • Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2015-2025
  • Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2014-2025
  • Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2015-2025
  • Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2014-2025
  • Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2015-2025
  • Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2013
  • Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2014
  • Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2019
  • Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2025
  • Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 4.6 Plavix: Revenue Forecast ($m), 2014-2025
  • Figure 4.7 Lovenox: Revenue Forecast ($m), 2014-2025
  • Figure 4.8 Xarelto: Revenue Forecast ($m), 2014-2025
  • Figure 4.9 Pradaxa: Revenue Forecast ($m), 2014-2025
  • Figure 4.10 Activase: Revenue Forecast ($m), 2014-2025
  • Figure 4.11 Effient: Revenue Forecast ($m), 2014-2025
  • Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2014-2025
  • Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2014-2025
  • Figure 4.14 Pletal: Revenue Forecast ($m), 2014-2025
  • Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2014-2025
  • Figure 4.16 Sandoz's Enoxaparin Sodium: Revenue Forecast ($m), 2014-2025
  • Figure 4.17 Fragmin: Revenue Forecast ($m), 2014-2025
  • Figure 4.18 Brilinta: Revenue Forecast ($m), 2014-2025
  • Figure 4.19 Eliquis: Revenue Forecast ($m), 2014-2025
  • Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2013
  • Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2014
  • Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2019
  • Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2025
  • Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014
  • Figure 7.1 The Top 10 Companies: Market Shares (%), 2013
  • Figure 7.2 The Top 10 Companies: Market Shares (%), 2014
  • Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2013-2025
  • Figure 10.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2014, 2019 and 2025

Companies Listed

  • Abbott Laboratories
  • Ablynx
  • Aché
  • Accord Healthcare
  • Actavis Totowa
  • AdvanceCor GmbH
  • Alchemia
  • Amneal Pharms
  • Amphastar Pharmaceuticals
  • Apotex
  • App Pharmaceuticals
  • ARCA biopharma
  • Armetheon
  • ARYx Therapeutics
  • Asahi Kasei Pharma America
  • Aspen
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Laboratories (subsidiary of Barr Pharmaceuticals)
  • Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
  • Bayer
  • Baylor College of Medicine, Houston, Texas
  • Bharat Biotech
  • BioVascular
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Capital TEN II
  • Canyon Pharmaceuticals
  • Committee on Medicinal Products for Human Use (CHMP)
  • CSL Behring
  • Daiichi Sankyo
  • Dexa Medica
  • Diakron Pharmaceuticals
  • Dr. Reddy's Laboratories
  • DuPont Merck
  • Eisai
  • Eli Lilly
  • EMS
  • Endo Laboratories
  • ESP Pharma
  • Eurofarma
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fournier Pharma
  • Gate Pharmaceuticals
  • Genentech
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • GlaxoSmithKline (GSK)
  • Grifols Therapeutics
  • Hercules Bioventures Partners
  • Hoechst Marion Roussell
  • Hospira
  • Hypermarcas
  • Indonesia University
  • Invagen Pharms
  • IPCA Labs
  • Isis Pharmaceuticals
  • Johns Hopkins Medicine
  • Johnson & Johnson (J&J)
  • Judicial Panel on Multidistrict Litigation (US)
  • Kowa
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical
  • LG Life Sciences
  • LIMES Institute
  • Lundbeck
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Mitsubishi
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mutual Pharmaceuticals
  • Mylan Pharmaceuticals
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • Novartis
  • Nuvelo
  • Organon
  • Otsuka Pharmaceutical Company
  • Pfizer
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • Pharmacia
  • PLIVA
  • PLx Pharma
  • Portola Pharmaceuticals
  • Pozen
  • Regado Biosciences
  • Roche
  • Roxane Laboratories
  • Sandoz
  • Sanofi
  • ScieGen Pharmaceuticals
  • Sun Pharmaceuticals Indusdtries
  • Takeda
  • Taro
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • ThromboGenics
  • Tianjin Medical
  • Tobira Therapeutics
  • Torrent Pharmaceuticals
  • Tufts Medical Center
  • Unified Health System (SUS)
  • Universidade Federal de São Paulo
  • University General Hospital
  • University of Insubria (Italy)
  • Upjohn AB
  • US Department of Justice
  • USL Pharma
  • Virginia Commonwealth University
  • Wockhardt
  • World Health Organization (WHO)
  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
  • Zydus Cadila
  • Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)
Back to Top